Table 1.
N | % | |
---|---|---|
Patients | 85 | 100% |
Sex | ||
Female | 45 | 52.9% |
Male | 40 | 47.1% |
Median age (IQR 1) | 13 (10–21) | |
Clinical status | ||
Asymptomatic | 20 | 23.5% |
Symptomatic | 65 | 76.5% |
Fever | 45 | 52.9% |
Cough and/or sore throat | 53 | 62.4% |
Cold | 15 | 17.6% |
Headache | 13 | 15.3% |
Otalgia and/or otitis | 3 | 3.5% |
Nausea and/or vomiting | 17 | 20.0% |
Diarrhea and/or abdominal cramps | 2 | 29.4% |
Dyspnea | 1 | 1.2% |
Neurological symptoms (stunning, confusion) | 3 | 3.5% |
General malaise | 33 | 38.8% |
Tested nasopharyngeal swab | 17 | 20.0% |
Positive for influenza A/H3N2 | 11 | 12.9% |
Positive for SARS-CoV-2 | 0 | |
Positive for rhinovirus | 4 | 4.7% |
Negative 2 | 4 | 4.7% |
Flu vaccination (2021/2022) | 14 | 16.5% |
Travel in the last 2 weeks | 19 | 22.4% |
1 IQR = interquartile range; 2 negative for all the tested viruses.